Page 98 - Haematologica Vol. 110 - January 2025

ARTICLE - LP-118: a promising treatment for CLL
J. Ravikrishnan et al.
ployed by and hold a position on the Board of Directors of Lupeng Pharmaceutical Inc., and report stock ownership in Lupeng Pharmaceutical Inc.
Contributions
JR is responsible for conceptualization, methodology, in- vestigation, formal analysis, visualization, and writing the original draft. DYDR is responsible for methodology, inves- tigation, formal analysis, visualization, writing, reviewing and editing. EM is responsible for methodology, investiga- tion, formal analysis, writing, reviewing and editing. THL, XM and SM are responsible for investigation, methodology, writing, reviewing and editing. CDW, JRS, AM, CL and AL are responsible for investigation. SS is responsible for compu- tational modeling. EP and TK are responsible for investi- gation, methodology. GL is responsible for resources and investigation. KAR, ASK, NJ and WGW are responsible for resources, writing, reviewing and editing. SAB is respon- sible for resources. MCC is responsible for methodology. MSD is responsible for methodology, writing, reviewing and editing. RL is responsible for writing, reviewing and editing. JCB is responsible for supervision, writing, reviewing and editing. FT and YiC are responsible for conceptualization, methodology, resources, funding acquisition, supervision, writing, reviewing and editing. YuC and SPA are responsible for conceptualization, methodology, resources, supervision, writing, reviewing and editing. YS is responsible for concep- tualization, methodology, supervision, writing, reviewing and
References
1. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107-1120.
2. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225-2236.
3. Tausch E, Close W, Dolnik A, et al. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica. 2019;104(9):e434-e437 .
4. Blombery P, Thompson ER, Nguyen T, et al. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood. 2020;135(10):773-777.
5. Blombery P, Anderson MA, Gong JN, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019;9(3):342-353.
6. Lucas F, Larkin K, Gregory CT, et al. Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/ PLCG2 mutations. Blood. 2020;135(24):2192-2195.
7. Guièze R, Liu VM, Rosebrock D, et al. Mitochondrial reprogramming underlies resistance to BCL2 inhibition in lymphoid malignancies. Cancer Cell. 2019;36(4):369-384.e13.
8. Herling CD, Abedpour N, Weiss J, et al. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun. 2018;9(1):727.
editing. JAW and DS are responsible for conceptualization, funding acquisition, methodology, resources, supervision, visualization, and writing the original draft.
Acknowledgments
The authors would like to thank patients and their families, and clinical and research personnel at The Ohio State Uni- versity and MD Anderson Cancer Center. We acknowledge the Leukemia Tissue Bank shared resource from the Ohio State University Comprehensive Cancer Center (P30CA016058). LP- 118 and RS4;11 cells were kindly provided for all the studies by Newave Pharmaceutical Inc. The authors thank Dr. Jan A. Burger (MD Anderson Cancer Center) for providing the NK Tert stromal cell line, and Dr. Natalia Baran (MD Anderson Cancer Center) and Dr. Marina Konopleva (Albert Einstein College of Medicine) for providing LOUCY, CCRF-CEM, PF- 382, and MOLT4 cell lines.
Funding
This work is supported in part by the Harry T. Mangurian Jr. Foundation, D. Warren Brown Foundation, and the NCI (R01 CA177292; to JAW and KR), and by the CLL Global Alliance (to DS and JAW) and the University of Texas MD Anderson CLL (to DS) and T/NK (to DS) Moonshots.
Data-sharing statement
Any relevant and original data are available from the cor- responding authors upon request.
9. Thijssen R, Diepstraten ST, Moujalled D, et al. Intact TP-53 function is essential for sustaining durable responses to BH3- mimetic drugs in leukemias. Blood. 2021;137(20):2721-2735.
10. Thijssen R, Tian L, Anderson MA, et al. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy. Blood. 2022;140(20):2127-2141.
11. Choudhary GS, Al-Harbi S, Mazumder S, et al. MCL1 and BCLXL- dependent resistance to the BCL2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6(1):e1593-e1593.
12. Haselager M, Thijssen R, West C, et al. Regulation of Bcl-XL by non-canonical NF-kB in the context of CD40-induced drug resistance in CLL. Cell Death Differ. 2021;28(5):1658-1668.
13. Haselager MV, Kielbassa K, Ter Burg J, et al. Changes in BCL2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood. 2020;136(25):2918-2926.
14. Yuda J, Will C, Phillips DC, et al. Selective MCL1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients. Commun Med (Lond). 2023;3(1):154.
15. Wang X, Bathina M, Lynch J, et al. Deletion of MCL1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 2013;27(12):1351-1364.
16. Wei AH, Roberts AW, Spencer A, et al. Targeting MCL1 in
Haematologica | 110 January 2025
90